阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALKS 阿尔凯默斯

未开盘 08-31 16:00:00 EDT

46.99

-0.42

-0.89%

盘后46.84

-0.15-0.32%

19:30 EDT

最高47.56	最低46.46	成交量144.09万
今开47.25	昨收47.41	日振幅2.32%
总市值78.83亿	流通市值72.83亿	总股本1.68亿
成交额6,771万	换手率0.93%	流通股本1.55亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALKS","market":"US","secType":"STK","nameCN":"阿尔凯默斯","latestPrice":46.99,"timestamp":1788206400000,"preClose":47.41,"halted":0,"volume":1440889,"hourTrading":{"tag":"盘后","latestPrice":46.84,"preClose":46.99,"latestTime":"19:30 EDT","volume":78107,"amount":3670317.428724,"timestamp":1788219001682,"change":-0.15,"changeRate":-0.003192,"amplitude":0.003192},"delay":0,"changeRate":-0.00885889052942406,"floatShares":155000000,"shares":167763272,"eps":0.388236,"marketStatus":"未开盘","change":-0.42,"latestTime":"08-31 16:00:00 EDT","open":47.25,"high":47.56,"low":46.46,"amount":67712636.236628,"amplitude":0.023202,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.388236,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":47.41,"preHourTrading":{"tag":"盘前","latestPrice":47.5,"preClose":47.41,"latestTime":"09:27 EDT","volume":4757,"amount":225546.480929,"timestamp":1788182866128,"change":0.09,"changeRate":0.001898,"amplitude":0.019827},"postHourTrading":{"tag":"盘后","latestPrice":46.84,"preClose":46.99,"latestTime":"19:30 EDT","volume":78107,"amount":3670317.428724,"timestamp":1788219001682,"change":-0.15,"changeRate":-0.003192,"amplitude":0.003192},"volumeRatio":1.086041,"optionData":{"bulkOrders":[{"symbol":"ALKS","call":false,"expireDate":1789704000000,"strike":"45.0","timestamp":1788196615563,"price":1.3,"volume":2850,"amount":370500,"type":"+"}]},"impliedVol":0.3824,"impliedVolPercentile":0.1195},"requestUrl":"/m/hq/s/ALKS/wiki","defaultTab":"wiki","newsList":[{"id":"1141245521","title":"《柳叶刀·神经病学》刊发阿尔凯默斯Alixorexton治疗1型发作性睡病II期临床积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141245521?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:31","pubTimestamp":1787610670,"startTime":"0","endTime":"0","summary":"《柳叶刀·神经病学》杂志近日正式发表了阿尔凯默斯旗下在研药物Alixorexton的Vibrance-1 II期临床研究数据。该研究聚焦于成年1型发作性睡病患者，结果令人振奋。这项研究结果在顶级医学期刊上的亮相，标志着阿尔凯默斯在睡眠障碍治疗领域迈出了坚实一步。Alixorexton作为一种新型治疗手段，其临床数据经过了严格的同行评审，最终获得权威刊物的认可。阿尔凯默斯公司表示，这些积极数据将进一步推动Alixorexton的研发进程，有望为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSIL","ALKS","FBT","IBRN","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177722074","title":"财报前瞻｜阿尔凯默斯本季度营收预计增长33.98%，机构观点暂无明显倾向","url":"https://stock-news.laohu8.com/highlight/detail?id=1177722074","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177722074?lang=zh_cn&edition=full","pubTime":"2026-07-22 00:16","pubTimestamp":1784650589,"startTime":"0","endTime":"0","summary":"阿尔凯默斯将于2026年07月28日发布最新季度财报，市场聚焦收入增长与盈利修复节奏。市场一致预期本季度阿尔凯默斯营收为4.58亿美元，同比增长33.98%，预计息税前利润为1,794.28万美元，同比增长-58.03%，预计调整后每股收益为-0.03美元，同比增长-106.72%；公司上季度披露的对本季度指引在公开信息中未获取到。上季度阿尔凯默斯营收为3.93亿美元，同比增加28.19%；毛利率为87.57%，归母净利润为-6,648.00万美元，净利率为-16.92%，调整后每股收益为-0.40美元，同比变动为-249.25%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜阿尔凯默斯本季度营收预计增长33.98%，机构观点暂无明显倾向","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139560681","title":"阿尔凯默斯Alixorexton长期扩展研究中期分析显示：对1型与2型发作性睡病成人患者日间觉醒维持改善效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139560681","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139560681?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:03","pubTimestamp":1783940600,"startTime":"0","endTime":"0","summary":"一项长期扩展研究的中期分析数据表明，阿尔凯默斯（Alkermes PLC）旗下药物Alixorexton在治疗成人1型与2型发作性睡病患者时，能够持续改善其日间觉醒状态。该分析结果揭示了该药物在延长治疗期间维持疗效的潜力，为患者提供了长期管理症状的新希望。研究聚焦于药物对核心症状——过度日间嗜睡的持续作用，评估了患者在扩展治疗阶段保持清醒能力的变化趋势。这一积极发现进一步支持了Alixorexton作为慢性神经疾病长期治疗方案的可能性，后续完整数据值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBT","MEDX","PSIL","PSCH","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187620650","title":"阿尔凯默斯 - Alixorexton在首次给药九个月后，于第24周在MWT和ESS上显示出持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187620650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187620650?lang=zh_cn&edition=full","pubTime":"2026-07-13 19:03","pubTimestamp":1783940597,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司宣布，其候选药物Alixorexton在首次给药九个月后，于临床试验的第24周评估中，在维持清醒测试和嗜睡量表两项关键指标上均表现出持续性的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","ALKS","PSIL","IBRN","PSCH","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160787890","title":"阿尔凯默斯与安尼尔终止授权仿制药供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160787890","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160787890?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:06","pubTimestamp":1783512380,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，阿尔凯默斯公司与其合作伙伴安尼尔公司已共同决定，自2026年7月6日起，终止双方此前达成的授权仿制药产品供应协议。\n这一变动标志着两家公司在该特定产品合作上的正式分道扬镳。协议的终止将影响相关仿制药未来的市场供应格局。文件披露了这一商业安排的调整，但未进一步阐述终止协议的具体原因或后续财务影响。\n市场参与者将密切关注此举对阿尔凯默斯业务管线及收入构成的潜在影响。同时，安尼尔公司的产品组合也可能因此次合作终止而面临调整。此次战略调整的长期影响，仍有待后续观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","IBRN","BK4139","MEDX","PSIL","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174177549","title":"异动解读｜阿尔凯默斯盘中上涨6.97%，嗜睡症新药二期试验达双重主要终点并启动三期","url":"https://stock-news.laohu8.com/highlight/detail?id=1174177549","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174177549?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:15","pubTimestamp":1782317725,"startTime":"0","endTime":"0","summary":"6月25日，阿尔凯默斯盘中上涨6.97%，报51.395美元/股，成交额8240.75万美元。公司已同步启动该药物的三期临床试验。该研究是首批证实食欲素类药物对2型嗜睡症有效的大型试验之一，表明其适用患者群体有望扩大至特发性嗜睡症及ADHD等更广泛适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126013632","title":"阿尔凯默斯在Sleep 2026大会上公布Alixorexton治疗2型发作性睡病成人患者的Vibrance-2二期研究详细积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1126013632","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126013632?lang=zh_cn&edition=full","pubTime":"2026-06-18 04:15","pubTimestamp":1781727315,"startTime":"0","endTime":"0","summary":"阿尔凯默斯（Alkermes PLC）在Sleep 2026学术会议上，详细公布了其候选药物Alixorexton用于治疗成人2型发作性睡病的Vibrance-2二期临床研究取得的积极成果。该研究数据展现了药物在改善患者核心症状方面的潜力，为后续开发提供了关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145115986","title":"异动解读 | 阿尔凯默斯盘中大涨6.37%，因Lumryz®三期研究获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145115986","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145115986?lang=zh_cn&edition=full","pubTime":"2026-05-13 02:21","pubTimestamp":1778610087,"startTime":"0","endTime":"0","summary":"阿尔凯默斯（ALKS）今日盘中股价大涨6.37%，引起了市场的广泛关注。消息面上，阿尔凯默斯宣布其针对特发性嗜睡症成人患者的Lumryz®（羟丁酸钠）缓释制剂，在关键性3期研究中取得了积极的顶线结果。初步数据显示，与安慰剂相比，Lumryz®达到了预设的主要疗效终点，显示出统计学上的显著改善，且安全性特征与已知信息一致。这一积极结果标志着阿尔凯默斯在睡眠障碍治疗领域取得了重要进展，为公司后续向监管机构提交新药申请奠定了基础，从而增强了投资者对公司未来前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139295905","title":"阿尔凯默斯公布Lumryz®治疗特发性嗜睡症的3期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139295905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139295905?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:05","pubTimestamp":1778583913,"startTime":"0","endTime":"0","summary":"阿尔凯默斯宣布，其针对特发性嗜睡症成人患者的Lumryz®（羟丁酸钠）缓释制剂，在名为Revitalyz℠的关键性3期研究中取得了积极的顶线结果。这项研究评估了该药物在改善患者日间过度嗜睡症状方面的有效性与安全性。初步数据显示，与安慰剂相比，Lumryz®达到了预设的主要疗效终点，显示出统计学上的显著改善。安全性特征与药物已知信息一致，未发现新的安全问题。这一积极结果标志着阿尔凯默斯在睡眠障碍治疗领域取得了重要进展，为公司后续向监管机构提交新药申请奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454353","title":"财报前瞻｜阿尔凯默斯本季度营收预计增18.33%，机构观点偏空","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454353","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164454353?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:11","pubTimestamp":1777349480,"startTime":"0","endTime":"0","summary":"阿尔凯默斯将于2026年05月05日美股盘前发布最新季度财报，市场关注收入回升与利润承压的取舍及研发进展节奏。市场一致预期本季度阿尔凯默斯营收为3.60亿美元，同比增18.33%；调整后每股收益为-0.57美元，同比-341.85%；息税前利润为-9,576.29万美元，同比-1,773.81%，公司上一季度披露的是全年指引，未提供本季度毛利率与净利润或净利率的明确指引。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜阿尔凯默斯本季度营收预计增18.33%，机构观点偏空","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117201237","title":"阿尔凯默斯将在2026年美国神经病学学会年会上公布阿立索瑞通治疗1型发作性睡病的Vibrance-1二期研究补充数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1117201237","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117201237?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:03","pubTimestamp":1776337383,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司宣布，将于2026年美国神经病学学会（AAN）年度会议上，展示其候选药物阿立索瑞通（Alixorexton）针对1型发作性睡病患者的Vibrance-1二期临床试验的补充数据集。\n此次公布的数据将提供关于阿立索瑞通疗效与安全性的更深层次见解，进一步阐明该疗法在管理1型发作性睡病核心症状方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183301439","title":"长期研究结果揭示Lybalvi®对精神分裂症阴性症状的疗效，发表于《临床精神病学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1183301439","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183301439?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:01","pubTimestamp":1776164490,"startTime":"0","endTime":"0","summary":"一项针对利巴维®（奥氮平和萨米多芬）对精神分裂症阴性症状影响的长期分析结果，近日在权威学术期刊《临床精神病学杂志》上正式发表。该研究提供了关于此药物长期疗效的重要临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624519909","title":"从减肥药加码睡眠障碍！礼来拟以最高78亿美元收购Centessa，进军发作性睡病及觉醒障碍治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2624519909","media":"华尔街见闻","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624519909?lang=zh_cn&edition=full","pubTime":"2026-04-01 21:20","pubTimestamp":1775049617,"startTime":"0","endTime":"0","summary":"礼来宣布以最高78亿美元收购Centessa，进军发作性睡病及觉醒障碍治疗领域。此举填补了其在失眠领域的布局空白，是中枢神经系统扩张战略的延续。食欲素类药物潜在市场远超睡眠障碍，有望延伸至神经退行性疾病、ADHD等更广泛领域，打开数十亿美元想象空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3769013","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1280957306.USD","LU2168564495.EUR","LU2324357040.USD","LU2112291526.USD","LU2746668461.USD","LU1267930730.SGD","LLII","LU0820562030.AUD","LU0889565916.HKD","LU0061475181.USD","LU0354030438.USD","LU2271345857.HKD","SGXZ57979304.SGD","LU0109391861.USD","IE0004445239.USD","IE00BWXC8680.SGD","SG9999014906.USD","LU1232071149.USD","LU2089283258.USD","IE00BN29S564.USD","IE00B4JS1V06.HKD","LU2237438978.USD","SGXZ81514606.USD","LU1551013342.USD","LU0097036916.USD","IE00B1BXHZ80.USD","LU1629891620.HKD","LU2237443549.SGD","SG9999018865.SGD","LU1720051017.SGD","LU2237443465.HKD","IE00BFSS8Q28.SGD","IE00BJJMRZ35.SGD","LU0823434740.USD","LU2237443895.HKD","LU2264538146.SGD","LU1127390331.HKD","LU1291159041.SGD","SG9999014880.SGD","IE0005OL40V9.USD","LU0106261372.USD","LU2168564149.EUR","LU2265009873.SGD","LU0198837287.USD","LU2237443382.USD","LU2750360997.AUD","LU1868836914.USD","LU2471134796.USD","LU1069344957.HKD","LU0256863902.USD","LU1712237335.SGD","IE0001KFT4U8.USD","SG9999013999.USD","LU0203202063.USD","LLYZ","LU2471134523.USD","IE0004445015.USD","SG9999017495.SGD","LU1064131342.USD","LU2168564222.USD","LU0672654240.SGD","LU2360106947.USD","LU0689472784.USD","LU1974910355.USD","LU0225283273.USD","LU2417539215.USD","LU2211815571.USD","LU1988902786.USD","SG9999015986.USD","LU2023250330.USD","LU2237443622.USD","IE00BK4W5L77.USD","LU0943347566.SGD","LU0114720955.EUR","LU0823416689.USD","LU0964807845.USD","LU2602419157.SGD","LU0385154629.USD","LU2491049909.HKD","BK4599","LU2462157665.USD","ELIS","LU0353189763.USD","IE00BK4W5M84.HKD","LU1868837300.USD","LU2028103732.USD","LU0316494557.USD","LU2491050071.SGD","LU2213496289.HKD","SG9999014914.USD","IE00BJJMRY28.SGD","LU0823434583.USD","LU0820561909.HKD","IE00BKDWB100.SGD","LU0203201768.USD","LU2063271972.USD","LU0882574055.USD","LU1323610961.USD","IE00BJT1NW94.SGD","CNTA","LU0109394709.USD","LU1093756168.USD","LU0708995401.HKD","LU2089284900.SGD","LU0882574139.USD","LU2106854487.HKD","SG9999001176.SGD","SGXZ31699556.SGD","LU2461242641.AUD","IE00BJJMRX11.SGD","LU2108987350.USD","LU2756315318.SGD","LU0158827781.USD","BK4585","LU1366192091.USD","LU0466842654.USD","LU2552382058.USD","LU1868837136.USD","LU0323591593.USD","LU2168563687.JPY","LU1057294990.SGD","LU2023250504.SGD","IE00B7KXQ091.USD","LU2168564065.EUR","LU2361044949.HKD","LU1551013425.SGD","BK4007","LU1720051108.HKD","LU0266013472.USD","LU2552382215.SGD","LU0456855351.SGD","SG9999014898.SGD","IE00B1XK9C88.USD","LU1145028129.USD","LU1035775433.USD","LU0256863811.USD","LU0096364046.USD","BK4516","LU2237443978.SGD","BK4533","LU0471298777.SGD","LU0787776722.HKD","LU2491050154.USD","LLY","LU0122379950.USD","LU0417517546.SGD","LU0238689110.USD","LU2456880835.USD","ALKS","LU2552382132.HKD","LU1023059063.AUD","LU2361044865.SGD","LU0058720904.USD","IE00B775H168.HKD","LU2471134879.HKD","LU0079474960.USD","LU0158827948.USD","LU0683600562.USD","LU2896262040.SGD","SG9999015945.SGD","LU0320765992.SGD","LU1868836757.USD","LU2357305700.SGD","LU2111349929.HKD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU0234572021.USD","SG9999001176.USD","SGXZ99366536.SGD","LLYX","LU0006306889.USD","LU2361045086.USD","LU0320765059.SGD","LU1093756325.SGD","LU2087625088.SGD","LU2750360641.GBP","LU0354030511.USD","SG9999015952.SGD","LU2236285917.USD","LU0094547139.USD","LU1989771016.USD","LU0432979614.USD","LU1548497426.USD","LU1804176565.USD","LU2756315664.SGD","LU1623119135.USD","IE00BFSS7M15.SGD","LU0640476718.USD","GB00BDT5M118.USD","LU0786609619.USD","LU2023251221.USD","LU1814569148.SGD","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BKPKM429.USD","LU1983299246.USD","SG9999015978.USD","ELIL","IE00B2B36J28.USD","SG9999018857.SGD","SGXZ51526630.SGD","LU0471298694.HKD","BK4588","LU0353189680.USD","LU1917777945.USD","LU2468319806.SGD","LU2089984988.USD","LU0820561818.USD","LU0289739699.SGD","LU1868836591.USD","LU1061106388.HKD","LU0210536198.USD","LU2471134952.CNY","LU2746668974.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143078608","title":"阿尔凯默斯启动评估Alixorexton治疗1型与2型发作性睡病的第三阶段Brilliance研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1143078608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143078608?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:01","pubTimestamp":1775041272,"startTime":"0","endTime":"0","summary":"阿尔凯默斯宣布，已正式启动其第三阶段Brilliance临床试验项目，旨在评估其在研药物Alixorexton针对1型与2型发作性睡病的治疗效果。这项关键研究的启动标志着该药物研发进程迈入重要阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621761686","title":"阿尔凯默斯在印度推出司美格鲁肽注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2621761686","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2621761686?lang=zh_cn&edition=full","pubTime":"2026-03-21 15:02","pubTimestamp":1774076543,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MNDmain","ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616827305","title":"阿尔凯默斯2025财年实现净利润2.42亿美元，同比减少34.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616827305","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616827305?lang=zh_cn&edition=full","pubTime":"2026-03-01 00:00","pubTimestamp":1772294459,"startTime":"0","endTime":"0","summary":"3月1日，阿尔凯默斯公布财报，公告显示公司2025财年净利润为2.42亿美元，同比减少34.95%；其中营业收入为14.76亿美元，同比减少5.26%，每股基本收益为1.47美元。从资产负债表来看，阿尔凯默斯总负债7.11亿美元，其中短期债务6.75百万美元，资产负债比为3.56，流动比率为3.56。机构评级：截至2026年3月1日，当前有17家机构对阿尔凯默斯目标价做出预测，其中目标均价为43.65美元，其中最低目标价为30.00美元，最高目标价为58.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000114a43b969b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260301000114a43b969b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511608563","title":"阿尔凯默斯2024财年实现净利润3.72亿美元，同比减少28.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511608563","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511608563?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:01","pubTimestamp":1739635282,"startTime":"0","endTime":"0","summary":"2月16日，阿尔凯默斯公布财报，公告显示公司2024财年净利润为3.72亿美元，同比减少28.32%；其中营业收入为15.58亿美元，同比减少6.31%，每股基本收益为2.22美元。机构评级：截至2025年2月16日，当前有12家机构对阿尔凯默斯目标价做出预测，其中目标均价为38.58美元，其中最低目标价为30.00美元，最高目标价为46.00美元。阿尔凯默斯从第三方购买活性药物产品，或者从第三方被许可方处获得活性药物产品，利用其技术配制产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000145a24729ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000145a24729ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511520912","title":"阿尔凯默斯盘中异动 临近午盘股价大涨5.02%报35.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511520912","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511520912?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:44","pubTimestamp":1739465061,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日00时44分，阿尔凯默斯股票出现波动，股价快速拉升5.02%。截至发稿，该股报35.18美元/股，成交量110.005万股，换手率0.68%，振幅6.00%。最近的财报数据显示，该股实现营业收入15.58亿美元，净利润3.72亿美元，每股收益2.22美元，毛利13.11亿美元，市盈率16.19倍。阿尔凯默斯股票所在的制药行业中，整体涨幅为0.72%。阿尔凯默斯从第三方购买活性药物产品，或者从第三方被许可方处获得活性药物产品，利用其技术配制产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021400442298844653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021400442298844653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511258320","title":"阿尔凯默斯盘中异动 下午盘大幅上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511258320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511258320?lang=zh_cn&edition=full","pubTime":"2025-02-13 02:15","pubTimestamp":1739384100,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日02时15分，阿尔凯默斯股票出现异动，股价大幅上涨5.02%。截至发稿，该股报33.57美元/股，成交量137.54万股，换手率0.85%，振幅6.48%。机构评级方面，在所有9家参与评级的机构中，78%的券商给予买入建议，22%的券商给予持有建议，无券商给予卖出建议。阿尔凯默斯股票所在的制药行业中，整体涨幅为0.52%。阿尔凯默斯从第三方购买活性药物产品，或者从第三方被许可方处获得活性药物产品，利用其技术配制产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213021501abcc8e02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213021501abcc8e02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALKS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107457445","title":"异动解读 | 阿尔凯默斯2024财年业绩超预期,促公司盘前大涨11.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107457445","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107457445?lang=zh_cn&edition=full","pubTime":"2025-02-12 21:44","pubTimestamp":1739367870,"startTime":"0","endTime":"0","summary":"生物制药公司阿尔凯默斯今日盘前大涨11.61%,引发市场关注。从公司最新财报来看,其业绩表现优异或是股价上涨的主因。阿尔凯默斯2024财年调整后每股收益达2.92美元,超出分析师预期的2.66美元,同比增长24.79%;全年销售额15.6亿美元,亦超出预期15.1亿美元,同比大增93.66%。展望2025年,阿尔凯默斯预计总收入将介于13.4亿至14.3亿美元,主力产品VIVITROL、ARISTADAi和LYBALVI净销售额合计达到8.15亿至8.35亿美元。可喜的财务表现和前景预期,支撑了阿尔凯默斯股价今日走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALKS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alkermes.com","stockEarnings":[{"period":"1week","weight":-0.0385},{"period":"1month","weight":-0.0408},{"period":"3month","weight":0.1372},{"period":"6month","weight":0.6048},{"period":"1year","weight":0.622},{"period":"ytd","weight":0.6794}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alkermes Public Limited Company于2011年5月4日在爱尔兰成立为一家私人有限公司，名称为Antler Science Two Limited（注册号498284）。该公司是一家完全整合的全球性生物制药公司，利用其科学专长和专有技术开发创新药物，改善患者的治疗效果。公司拥有多元化的产品组合，包括20多种商业药物产品和大量临床候选产品，用于治疗中枢神经系统疾病，如成瘾、精神分裂症和抑郁症。","yearOnYearQuotes":[{"month":1,"riseRate":0.771429,"avgChangeRate":0.090924},{"month":2,"riseRate":0.428571,"avgChangeRate":0.050544},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.039697},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.029255},{"month":5,"riseRate":0.571429,"avgChangeRate":0.057545},{"month":6,"riseRate":0.485714,"avgChangeRate":0.010224},{"month":7,"riseRate":0.514286,"avgChangeRate":0.020537},{"month":8,"riseRate":0.472222,"avgChangeRate":0.04151},{"month":9,"riseRate":0.428571,"avgChangeRate":0.001956},{"month":10,"riseRate":0.514286,"avgChangeRate":0.03285},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.011873},{"month":12,"riseRate":0.685714,"avgChangeRate":0.05445}],"exchange":"NASDAQ","name":"阿尔凯默斯","nameEN":"Alkermes PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔凯默斯(ALKS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔凯默斯,ALKS,阿尔凯默斯股票,阿尔凯默斯股票老虎,阿尔凯默斯股票老虎国际,阿尔凯默斯行情,阿尔凯默斯股票行情,阿尔凯默斯股价,阿尔凯默斯股市,阿尔凯默斯股票价格,阿尔凯默斯股票交易,阿尔凯默斯股票购买,阿尔凯默斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔凯默斯(ALKS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔凯默斯(ALKS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}